Cannabis Use in Patients with Fibromyalgia: Effect on Symptoms Relief and Health-Related Quality of Life

Abstract

BackgroundThe aim of this study was to describe the patterns of cannabis use and the associated benefits reported by patients with fibromyalgia (FM) who were consumers of this drug. In addition, the quality of life of FM patients who consumed cannabis was compared with FM subjects who were not cannabis users.MethodsInformation on medicinal cannabis use was recorded on a specific questionnaire as well as perceived benefits of cannabis on a range of symptoms using standard 100-mm visual analogue scales (VAS). Cannabis users and non-users completed the Fibromyalgia Impact Questionnaire (FIQ), the Pittsburgh Sleep Quality Index (PSQI) and the Short Form 36 Health Survey (SF-36).ResultsTwenty-eight FM patients who were cannabis users and 28 non-users were included in the study. Demographics and clinical variables were similar in both groups. Cannabis users referred different duration of drug consumption; the route of administration was smoking (54%), oral (46%) and combined (43%). The amount and frequency of cannabis use were also different among patients. After 2 hours of cannabis use, VAS scores showed a statistically significant (p<0.001) reduction of pain and stiffness, enhancement of relaxation, and an increase in somnolence and feeling of well being. The mental health component summary score of the SF-36 was significantly higher (p<0.05) in cannabis users than in non-users. No significant differences were found in the other SF-36 domains, in the FIQ and the PSQI.ConclusionsThe use of cannabis was associated with beneficial effects on some FM symptoms. Further studies on the usefulness of cannabinoids in FM patients as well as cannabinoid system involvement in the pathophysiology of this condition are warranted.

Clinical trials of medicinal cannabis for appetite‐related symptoms from advanced cancer: a survey of preferences, attitudes and beliefs among patients willing to consider participation

“…Comments offered by respondents to the current survey are consistent with findings from a previous survey and qualitative studies on medicinal cannabis use. Cannabis users have consistently reported anecdotal evidence for symptom improvement, although the proportion reporting benefit has varied widely . The only previous Australian survey ( n = 128) found that around a quarter of medicinal cannabis users across a variety of health conditions used it for appetite loss, and nearly all reported ‘great’ or ‘good’ relief .…”

Medical cannabis: Another piece in the mosaic of autoimmunity?

“…After cannabis consumption, the cannabis‐users group exhibited a reduction in pain and stiffness as well as an increase in relaxation, somnolence, and feeling well, and achieved scores of mental health component in Short Form Health Survey‐36. However, no significant improvements were found in Short Form Health Survey‐36 other components as well as in the Fibromyalgia Impact Questionnaire and the Pittsburgh Sleep Quality Index …”

Spontaneous, anecdotal, retrospective, open-label study on the efficacy, safety and tolerability of cannabis galenical preparation (Bedrocan)

“…However, the high concentration of CBG (16 mg/g), a phytocannabinoid known to be an α‐2 adrenoreceptor and the serotonin 1A receptor (5‐ HT1A) agonist, and terpenoid myrcene (5 mg/g) in this formulation could explain the analgesic and myorelaxant effect recorded in most patients (75%). Also, the improvement of neurologic symptoms (improvement in mood and concentration) might be due to this selected formula containing Δ 9 ‐THC and CBD at the ratio of 22 : 1 that could mitigate the beta‐amyloid peptide (Aβ) level‐evoked neuroinflammatory and neurodegenerative responses . A recent study in vitro evidenced that low doses of Δ 9 ‐THC solution (100 μl at 2× concentrations in each well) added in mouse neuroblastoma cell line (N2a/AβPPswe cells) lowed the Aβ level, the total and phosphorylated GSK‐3β levels (protein kinase that has a key role in the pathogenesis of both sporadic and familial AD) .…”